- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04217382
Pre Transplantation Melanoma (MPG)
Pre Transplantation Melanoma : Retrospective and Prospective Multicenter Observational Study
Melanoma incidence is increase in global population and number of transplantation also. However immunosuppressor increase recurrence risk of melanoma.
There are more and more cases of eligible patients to transplant with an antecedent of melanoma. There is no guideline yet.
Main objective is survival time without melanoma recurrence in this population to do guideline of time limit or not between melanoma and transplantation by stage.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Rhone
-
Lyon, Rhone, France, 69003
- service de dermatologie - hopital Edouard Herriot
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patient with an antecedent of melanoma before transplantation
- Not opposite to participate
Exclusion Criteria:
- Under the age of 18
- patient under Guardianship
- patient not affiliated with a health system
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
survival time without melanoma recurrence
Time Frame: at enrollment
|
Delay in recurrence-free survival since diagnosis and since transplantation
|
at enrollment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Emilie DUCROUX, MD, Service de Dermatologie, Hôpital Edouard Herriot, Lyon
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69HCL19_0636
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Melanoma
-
National Cancer Institute (NCI)TerminatedRecurrent Melanoma | Stage IV Melanoma | Acral Lentiginous Malignant Melanoma | Lentigo Maligna Malignant Melanoma | Nodular Malignant Melanoma | Solar Radiation-related Skin Melanoma | Superficial Spreading Malignant MelanomaUnited States
-
Grupo Español Multidisciplinar de MelanomaGlaxoSmithKlineCompletedMalignant Melanoma Stage IV | Malignant Melanoma Stage IIIcSpain
-
Centre Hospitalier Universitaire de NiceUnknownMalignant Melanoma Stage III | Malignant Melanoma Stage IV
-
Hoffmann-La RocheCompletedMalignant Melanoma, CancerHungary
-
Hoffmann-La RocheCompletedMalignant Melanoma, NeoplasmsUnited States, South Africa, Croatia, Brazil, Egypt
-
Lynn E. Spitler, MDGenentech, Inc.; Celgene CorporationCompletedMetastatic Malignant MelanomaUnited States
-
Hoffmann-La RocheCompletedMalignant Melanoma, NeoplasmsKorea, Republic of, Brazil, United States, Canada, Cyprus
-
Hoffmann-La RocheCompletedMalignant Melanoma, NeoplasmsSpain, New Zealand, Hungary, Serbia, Germany, Portugal, Netherlands, Greece, Australia
-
National Cancer Institute (NCI)GlaxoSmithKline; Novartis PharmaceuticalsActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable...United States
-
Dr. Ronnie ShapiraNot yet recruitingMetastatic Melanoma | Malignant Melanoma | Immunotherapy | Malignant Melanoma Stage IV | BRAF V600E
Clinical Trials on patient with melanoma pre transplantation
-
Central Hospital, Nancy, FranceNot yet recruitingPatients Hospitalized for Pre-eclampsiaFrance
-
Saglik Bilimleri Universitesi Gulhane Tip FakultesiCompleted
-
University of California, DavisCompletedMelanoma | Malignant MelanomaUnited States
-
John MascarenhasNational Cancer Institute (NCI); Novartis; Incyte Corporation; Myeloproliferative...TerminatedPrimary Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera MyelofibrosisUnited States, Canada, United Kingdom
-
Beth Israel Deaconess Medical CenterOpenBiomeCompletedIrritable Bowel SyndromeUnited States
-
CHU de ReimsCompletedMetastatic MelanomaFrance
-
Institut für Pharmakologie und Präventive MedizinEdwards LifesciencesRecruiting
-
Brigham and Women's HospitalCricoCompletedAdverse Event | Transitions of Care | General Medicine | Discharge ChecklistUnited States
-
Rehmat Memorial Post Graduate Dental Teaching HospitalCompletedOral Hygiene | PhotographsPakistan
-
Vejle HospitalThe Ottawa Hospital Research InstituteRecruiting